XTalks

APRIL 7, 2021

In this episode of the Xtalks Life Science Podcast, Ayesha discusses a report from the Center for Countering Digital Hate (CCDH) and Anti-Vax Watch that shows there are just 12 people behind 65 percent of all online anti-vaccine disinformation. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 59

Life Science Vaccination Vaccine Trials 59

XTalks

DECEMBER 30, 2024

has announced promising Phase IIb results for cenerimod, an investigational drug targeting immune system dysfunction in moderate-to-severe systemic lupus erythematosus (SLE). SLE is an autoimmune disease where the immune system attacks healthy tissues, causing inflammation, pain and potential organ damage. Viatris Inc.

Immune Response 52

Immune Response Gene Expression Drugs Trials 52

XTalks

DECEMBER 29, 2023

Tarlatamab is an investigational drug currently undergoing clinical trials to assess its efficacy in patients with two distinct types of neuroendocrine cancer: SCLC and neuroendocrine prostate cancer (NEPC). As a bispecific T-cell engager immunotherapy, tarlatamab directs the patient’s T cells to attack cancer cells exhibiting DLL3.

Clinical Trials 119

Clinical Trials Clinical Trials FDA Approval Trials 119

pharmaphorum

MARCH 4, 2021

UK chancellor Rishi Sunak has announced a budget loaded with initiatives designed to kick-start the UK’s economy as it recovers from the coronavirus pandemic, with vaccine development, pharma and life sciences playing a key role. A scheme providing £500 payments to people self-isolating has been extended in England until the summer.

Vaccination 105

Vaccination Vaccine Development Life Science 105

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, The inhalant version.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

XTalks

JANUARY 8, 2021

Both vaccines demonstrated an effectiveness of about 95 percent in Phase III clinical trials. Others have voiced concern that clinical trials have not evaluated half doses nor different dosing schedules. The agency says, “These are all reasonable questions to consider and evaluate in clinical trials.

Vaccination 144

Vaccination Vaccine Clinical Trials Clinical Trials 144

XTalks

JANUARY 20, 2025

Sasanlimab, a subcutaneous anti-PD-1 therapy, offers a novel immunotherapy approach that enhances the anti-tumor immune response. Having its own checkpoint inhibitor to combine with its ADCs rather than from other companies would make things easier to coordinate in clinical trials.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 10, 2020

Phase1b/2 clinical study to be conducted in the United States and several European countries. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. Tiziana Life Sciences January 9, 2020 Press Release ( [link] ). . Crohn’s Disease Therapeutics Market Size $4.7 and Europe.

Life Science 40

Life Science Clinical Trials Clinical Trials Trials 40

XTalks

JANUARY 20, 2025

Sasanlimab, a subcutaneous anti-PD-1 therapy, offers a novel immunotherapy approach that enhances the anti-tumor immune response. Having its own checkpoint inhibitor to combine with its ADCs rather than from other companies would make things easier to coordinate in clinical trials.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

XTalks

AUGUST 13, 2020

As the rush for a COVID-19 vaccine continues, healthcare services company Kaiser Permanente has joined in on the clinical testing of Pfizer Inc. and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon. Kaiser began Phase III trials of the vaccine at the end of July.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

XTalks

MARCH 13, 2023

The US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) held a recent town hall where three experts from the regulator provided guidance on how to design and conduct gene therapy clinical trials for rare diseases. All except for Adstiladrin were cleared for rare disease indications.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

pharmaphorum

JULY 20, 2021

The phase 3 trial being run in support of approval is using a two-shot regimen, with the first dose targeting the original SARS-CoV-2 virus and the second targeting beta (B.1.351) 1.351) variant first identified in South Africa. The post EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine appeared first on.

Vaccination 98

Vaccination Vaccine Protein Immune Response 98

XTalks

NOVEMBER 23, 2020

The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

pharmaphorum

NOVEMBER 29, 2022

Number of on-going clinical trials: 14. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. Locations: 3 (US HQ, Korea office, Korea R&D center). Number of employees: 90+ (as of Oct. Creation: Jan.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Engineer 105

XTalks

FEBRUARY 19, 2024

The study compared the immune responses evoked by Moderna’s mRNA vaccine to those generated by a previous vaccine candidate, namely, the MF59-adjuvanted glycoprotein B (gB) proten subunit vaccine (gB/MF59) developed by Sanofi. During pregnancy, CMV infection is responsible for causing severe birth defects and brain damage in newborns.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

XTalks

SEPTEMBER 5, 2023

Investigation of the possibility of VAED is crucial during clinical trials for decision-making on vaccine licensing by regulatory agencies. In the majority of cases, the risk of VAED is brought to light during preclinical stages or early clinical trial phases.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

XTalks

JULY 31, 2024

Alopecia areata can be triggered by genetics, immune system dysfunction and environmental factors. Leqselvi works by selectively inhibiting the Janus kinases (JAK) JAK1 and JAK2, pathways that play a key role in this misguided immune response.

Immune Response 105

Immune Response Dermatology Clinical Trials Clinical Trials 105

XTalks

NOVEMBER 22, 2022

In clinical trials, the treatment delayed stage 3 disease onset for about two years compared with the placebo. Tzield’s FDA approval was based on safety and efficacy data from a randomized, double-blind, event-driven, placebo-controlled trial involving 76 patients with stage 2 type 1 diabetes.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

XTalks

DECEMBER 14, 2021

Moderna revealed the first interim results from a small, Phase I study of its mRNA-based influenza vaccine, which showed that the vaccine had no significant safety concerns and elicited immune responses against four strains of the influenza virus. There were no significant safety findings reported through day 29. Mixed Results.

Vaccination 98

Vaccination Vaccine Immune Response Antibody 98

XTalks

JULY 28, 2021

While Merck’s previous shot, Pneumovax 23, defends against 23 serotypes and has been on the market for almost four decades, the immune responses it generates are not as durable as Prevnar 13. This is why Pfizer’s Prevnar 13 has dominated the pneumonia vaccine space for more than a decade.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. How the Type 1 Diabetes Vaccine Works. islet cells of the organ, giving rise to the disease. cells of the pancreas.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

XTalks

JANUARY 20, 2021

While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.

Immune Response 52

Immune Response Research Allergies Protein 52

XTalks

JUNE 15, 2022

Adjuvants can help boost the effectiveness of a vaccine and elicit a stronger immune response. Clinical Trial Results. Results from the PREVENT-19 pediatric expansion trial showed that the vaccine was also effective in adolescents aged 12 to 17 years. NVX-CoV2373 also includes an adjuvant called Matrix-M.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

XTalks

JULY 2, 2021

The CDC says that while “clinical trials that study the safety of COVID-19 vaccines and how well they work in pregnant people are underway or planned … based on how these vaccines work in the body, experts believe they are unlikely to pose a risk for people who are pregnant.”.

Vaccination 105

Vaccination Vaccine Protein Immune Response 105

XTalks

MAY 30, 2023

Novel treatments: Ongoing research into new treatments for MS include novel immunomodulatory drugs that aim to modulate or suppress the immune response that attacks the myelin sheath in MS. Clinical trials have shown that HSCT can halt disease progression in some people with aggressive forms of MS, although it is a high-risk procedure.

Genetics 98

Genetics Research Immune Response Drugs 98

XTalks

NOVEMBER 10, 2020

Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. Adjuvants are used to help stimulate stronger vaccine immune responses. Based on the encouraging Phase I data, Medicago says it plans to proceed with its Phase II/III trials.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Delveinsight

FEBRUARY 11, 2021

Verily collaborates with Janssen to launch COVID-19 immune response study. Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes. .

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

The Pharma Data

JANUARY 3, 2021

Weber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientist. Both will help NexImmune advance current early-stage clinical trials and will guide Company’s translational efforts to develop new immunotherapy products. GAITHERSBURG, Md.,

Immune Response 40

Immune Response Clinical Trials Clinical Trials Development 40

XTalks

NOVEMBER 10, 2020

The early data is for one of four COVID-19 vaccines currently being tested in clinical trials by the companies as part of Pfizer’s BNT162 mRNA-based vaccine program called ‘Project Lightspeed’ for SARS-CoV-2, the virus causing the current global pandemic. Related: Moderna’s COVID-19 Vaccine Fast-Tracked to Phase II Trials.

Vaccination 75

Vaccination Vaccine Trials Clinical Trials 75

The Pharma Data

DECEMBER 23, 2020

Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported; only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. ” Findings from the Phase 1 Clinical Trial. mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

NOVEMBER 15, 2020

16, 2020 /PRNewswire/ — Cytiva , a global life sciences leader, is supporting Clover Biopharmaceuticals , a global clinical-stage biotechnology company, to help accelerate the development and manufacturing of a protein-based S-Trimer subunit vaccine candidate. SHANGHAI , Nov. About Cytiva.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52

XTalks

FEBRUARY 3, 2021

These vaccine productions had gone through the regular steps starting with three clinical trials, publishing the trial results then manufacturing the vaccine. Herd Immunity and Equitable Access to COVID-19 Vaccines. The safety of the vaccines is continuously monitored.”.

Vaccination 98

Vaccination Vaccine Immune Response Manufacturing 98

XTalks

SEPTEMBER 23, 2021

one month after administration of the second dose, which indicates a strong immune response. Results showed that the SARS-CoV-2–neutralizing antibody geometric mean titer (GMT) was 1,197.6 This was non-inferior, or comparable, to the GMT of 1146.5

Vaccination 98

Vaccination Vaccine Trials Antibody 98

XTalks

AUGUST 5, 2022

The featured speakers will discuss how to facilitate trial participation in rare disease. Stelara Clinical Trial Results. monoclonal antibody that inhibits interleukin (IL) IL-12 and IL-23 cytokines, which are involved in inflammatory and immune responses. Psoriatic Arthritis Clinical Trial Pipeline.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

XTalks

DECEMBER 12, 2023

Within the next few months we’re expecting topline results from a Phase III clinical trial on a next-generation fibrinogen, an important plasma protein essential for blood clotting. What are key pipeline initiatives for Grifols in the coming years? Schüttrumpf: We’re excited about what’s coming down the road.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

XTalks

JUNE 10, 2024

The cause of psoriasis has yet to be fully understood, but scientists estimate its origins in genetic and environmental factors and immune dysregulation (where the body is unable to control its immune response).

Immune Response 52

Immune Response Dermatology Clinical Trials Clinical Trials 52